ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 153 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2017. The put-call ratio across all filers is 2.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $271,632 | -93.6% | 170,838 | -74.9% | 0.00% | -95.8% |
Q4 2022 | $4,233,472 | +383.3% | 679,530 | +393.3% | 0.02% | +380.0% |
Q2 2022 | $876,000 | -64.9% | 137,744 | -74.4% | 0.01% | -64.3% |
Q1 2022 | $2,496,000 | -22.2% | 537,856 | -16.2% | 0.01% | -22.2% |
Q4 2021 | $3,210,000 | +3.7% | 642,035 | +150.1% | 0.02% | -10.0% |
Q3 2021 | $3,094,000 | +125.8% | 256,761 | +296.3% | 0.02% | +122.2% |
Q2 2021 | $1,370,000 | +6.1% | 64,794 | +30.5% | 0.01% | -18.2% |
Q4 2020 | $1,291,000 | +236.2% | 49,643 | +670.7% | 0.01% | +57.1% |
Q4 2019 | $384,000 | +48.3% | 6,441 | +15.6% | 0.01% | 0.0% |
Q2 2019 | $259,000 | -94.2% | 5,571 | -91.8% | 0.01% | -92.8% |
Q4 2017 | $4,455,000 | -2.8% | 67,666 | -26.0% | 0.10% | -4.9% |
Q3 2017 | $4,585,000 | -2.2% | 91,480 | -9.7% | 0.10% | -12.8% |
Q2 2017 | $4,689,000 | +131.2% | 101,319 | +76.4% | 0.12% | +138.8% |
Q1 2017 | $2,028,000 | -59.9% | 57,435 | -73.2% | 0.05% | -79.4% |
Q3 2015 | $5,052,000 | – | 214,162 | – | 0.24% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |